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Myeloproliferative neoplasms (MPN) are chronic marrow disorders with variable prognoses. Most patients
with polycythemia vera, essential thrombocythemia, or even primary myeloﬁbrosis (PMF) are successfully
treated with conservative strategies for years or even decades, and recent data suggest that even in patients
with high-risk disease, in particular those with PMF, life expectancy can be extended by treatment with janus
kinase (JAK2) inhibitors. However, none of those modalities are curative, and after marrow failure develops,
the disease “accelerates,” or transforms to acute leukemia, the only option able to effectively treat and, in fact,
cure MPN is allogeneic hematopoietic cell transplantation (HCT). Outcome is superior if HCT is performed
before leukemic transformation occurs. Several reports document survival in unmaintained remission beyond
10 years. The most recent analyses show reduced regimen-related mortality (less than 10% or even 5% at
day 100) and progressively improved survival with both HLA-identical sibling and unrelated donors. The
development of low/reduced-intensity conditioning regimens has contributed to the improved success rate
and has allowed successful HCT in patients in their seventh and even eighth decade of life. We propose,
therefore, that HCT should be offered to ﬁt patients in these age groups and should be covered by their
respective insurance carriers.
 2015 The Authors. Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Trans-
plantation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).INTRODUCTION considerably. Some patients show progression to marrow
Primary myeloﬁbrosis (PMF) is a rare myeloproliferative
neoplasm (MPN), that occurs primarily in older individuals,
with a median age at diagnosis of 67 years [1]. Median life
expectancy is 4 to 5 years. However, the prognosis variesdgments on page 1887.
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within 1 year or 2, whereas others have a course that may
extend over a decade or more.
Patients who present originally with other MPNs, such as
polycythemia vera (PV) or essential thrombocythemia (ET),
tend to be younger at diagnosis and typically show a more
protracted course, with median life expectancies approach-
ing 2 decades. However, a proportion of those patients will
also experience an acceleration of their disease with marrow
ﬁbrosis and marrow failure or transformation to AML.ociety for Blood and Marrow Transplantation. This is an open access article
0/).
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strategies (eg, hydroxyurea or interferon) for years, but
management of more advanced disease is challenging. The
prognosis is especially poor with transformation to AML,
which is associated with a median survival (after trans-
formation) of a few months. One-year overall survival,
regardless of treatment intervention, is less than 15% [2,3].
The use of recently introduced compounds that interfere
with Janus kinase (JAK) function, so called JAK inhibitors,
has resulted in profound symptomatic improvement and
reduction in spleen size in patients with myeloﬁbrosis (MF)
and may modify the natural course of the disease. Jakaﬁ
(ruxolitinib; Incyte, Wilmington, DE, USA), an oral JAK1/JAK2
inhibitor, has been approved by the Food and Drug Admin-
istration for the treatment of patients with intermediate- or
high-risk MF, including PMF, post-PV MF, and post-ET MF,
and has been shown to improve patients’ quality of life [4,5],
although it may be associated with the development of
anemia. In 2 phase III studies of patients with Dynamic In-
ternational Prognostic Scoring System (DIPSS; see Table 1)
intermediate-2 or high-risk MF, ruxolitinib was associated
with improvement in survival compared with placebo-
treated patients (COMFORT-I study) or patients who
received “best available therapy” (COMFORT-II study) [4,8].
The COMFORT-II study showed a modest survival advantage
for patients who had been treated for more than 3 years [8].
However, although recent data suggest that molecular re-
missions can be achieved with ruxolitinib [9], this compound
is not curative and may not affect the risk for transformation
to AML. At 3 years, 60% of patients are off treatment because
of toxicity or a lack of or loss of response. Therefore, although
it is appropriate to offer symptomatic patients and those
with morbid splenomegaly a trial of ruxolitinib, physicians
and patients must remain alert to the possibility of disease
progression (eg, cytogenetic/clonal evolution, trans-
formation to AML) while on such therapy. Particularly, pa-
tients who are considered candidates for HCT must be
monitored carefully in order not to miss the opportunity
of receiving a transplant before prominent disease
progression.TRANSPLANTATION
At present, allogeneic hematopoietic cell transplantation
(HCT) is the only modality with proven curative potential; in
essence, HCT currently represents the only deﬁnitive therapyTable 1
Parameters in Current Prognostic Scoring Systems for Primary Myeloﬁbrosis
Parameter DIPSS [6] MIPSS [7]
Age 65 (1 point) versus <65 >60 (.5 Points)
Leukocyte Count
( 109/L)
>25 (1 point) versus 25 N/A
Hemoglobin (g/dL) <10 (2 points) versus 10 <10 (.5 points)
Constitutional
symptoms
Present (1 point) Present (0.5 points)
Circulating blasts 1% (1 point) versus absent N/A
Platelets ( 109/L) N/A <200 (1 point)
Triple negative* N/A Present (1.5 points)
JAK2, V617 F, or
MPL mutation
N/A Present (.5 points)
ASXL1 mutation N/A Present (.5 points)
SRSF2 mutation N/A Present (.5 points)
MIPSS indicates modiﬁed DIPSS; N/A, not applicable.
* Triple negative indicate wild type for JAK2 (V617 F), MPL, and CALR
mutations.for MPN. Because of this, the number of patients undergoing
HCT for MPN has increased progressively (Figure 1).
Transplantation for Hematopoietic Failure
Numerous clinical trials have shown the efﬁcacy of allo-
geneic HCT (Table 2). In a prospective multicenter phase II
trial involving 66 patients, with a median follow-up of
2 years, Rondelli et al. observed survival of 75% after trans-
plantation from HLA-identical siblings; results were inferior,
with survival of 32%, in patients who received a transplant
from unrelated donors [22]. In another prospective phase II
multicenter trial that enrolled 103 patients, 5-year overall
survival was 67% [15].
In a retrospective registry analysis of results in 289
patients ranging from 18 to 73 years of age, long-term sur-
vival was observed in about one third of patients; however,
the probability of survival was dependent upon the trans-
plantation conditioning regimen and, similar to the obser-
vations of Rondelli et al., the source of stem cells used for the
transplantation [13]. Another retrospective registry analysis
of data on 233 patients showed similar results, with 5-year
survival ranging from 56% to 34%, dependent on donor
type and stem cell source [23]. In that cohort, 27% of patients
were older than 60 years, and after adjusting for other risk
factors, multivariate analyses failed to show an association of
age at HCT with overall survival or progression-free survival.
The relative risk of overall survival for patients >60 years,
compared with that for patients 41 to 60 years of age, was .77
(95% conﬁdence interval, .52 to 1.12; P ¼ .171), and the
relative risk for progression-free survival was 1.02 (95%
conﬁdence interval, .72 to 1.45; P ¼ .904). Additional similar
results were reported by Lussana et al. [24] in a retrospective
cohort of 250 patients, 22 to 75 (median, 56) years of age,
with post-PV or post-ET MF, showing a 3-year overall sur-
vival of 55%. Survival was affected negatively by older age, as
also noted in other studies [20], by transformation of the
disease to AML [25,26], and by the use of unrelated rather
than sibling donors. However, these transplantations were
carried out as far back as 1994, and analysis of results in
patients who underwent transplantation more recently does
not show a signiﬁcantly inferior outcome with HLA-matched
unrelated donors [21,27].
Of course, HCT in older patients is subject to selection bias
by focusing on ﬁt patients without comorbidities [28].
However, this limitation applies to all diagnoses (and all ageFigure 1. Increase in transplantations for myeloﬁbrosis since 1997 by patient
age and source of stem cells. Data provided by Center for International Bone
Marrow Transplant Research. BM indicates bone marrow; PBSC, mobilized
peripheral blood stem cells; CB, cord blood cells.
Table 2
Selected Reports of HCT Outcomes in Patients with Myeloﬁbrosis [10]
Reference Timeline
of HCT
n Age, median
(range), yr
Conditioning Regimen Patients
with RIC, %
NRM PFS OS Comment
Rondelli [11] NR 21 54 (27-68) Multiple 100 10% at 1 yr 81% at 2.7 yr 85% at 2.7 yr Extensive cGVHD in 44%; 2 patients needed DLI for
100% donor chimerism; resolution of ﬁbrosis and
splenomegaly in majority
Kerbauy [12] NR 104 49 (18-70) Multiple, Bu/Cy (62%) 9 35% at 5 yr NR 61% at 5 yr 3 Syngeneic donors, 54 of the patients overlapped
with a prior report [13]; targeted Bu improved OS;
comorbidity score had impact on survival
Patriarca [14] 1986-2006 100 49 (21-68) Multiple, Bu/Cy 50% of full
intensity; Thiotepa þ Cy
in 46% of RIC
52 43% at 3 yr 35% at 3 yr 42% at 3 yr AHCT before 1995; Unrelated donor and longer
interval from diagnosis predicted worse outcome
but not conditioning intensity; relapse at 2 yr 41%,
progressive decline in NRM over 20 yr studied
Kroger [15] 2002-2007 103 55 (32-68) Flu-Bu (100%) 100 16% at 1 yr 51% at 5 yr 67% at 5 yr First prospective study in MF, cGVHD in 43%; 12%
NRM for fully matched donor AHCT; age >55 yr and
HLA mismatch adversely affected OS; JAK2-positive
recipients had better EFS and OS; splenectomy
increased risk of relapse
Ballen [13] 1989-2002 289 47 (18-73) Multiple, Bu/Cy (43%) 21 35% siblings 50%
for URD at 5 yr
33% siblings 27%
for URD at 5 yr
37% siblings 30%
for URD at 5 yr
Relapse at 5 yr, 32% in sibling and 23% in URD;
performance status, peripheral blasts sibling donor
status impacted OS; RIC was similar in outcomes,
except early NRM
Alchalby [16] 1999-2009 162 56 (32-73) Flu-Bu in 96% 100 22% at 1 yr 46% at 5 yr 62% at 5 yr 82 patients reported previously; age and HLA
mismatch impacted NRM; 23% relapse at 3 yr;
clearance ofmutated JAK2 atmedian of 96 days, and
this reduced relapse risk
Bacigalupo [17] 1994-2007 46 51 (24-67) Thiotepa-Cy þ melphalan 100 24% at 5 yr NR 45% at 5 yr A risk score based on transfusion history,
spleen >22 cm and alternative donor use predicted
lower OS; no beneﬁt for splenectomy
Robin [18] 1997-2008 147 53 (20-68) Multiple 69 39% at 4 yr 32% at 4 yr 39% at 4 yr 19% patients had LT; poor outcome with
mismatched donor
Samuelson [19] 1999-2007 30 65 (60-78) Multiple 63 13% at day 100 40% at 3 yr 45% at 3 yr Studied outcomes in patients 60 yr, 7 patients had
preceding LT
Ditschkowski [20] 1994-2010 76 50.5 (22-67) Multiple NR 36% at 5 yr 50% at 5 yr 53% at 5 yr Signiﬁcant high risk of relapse in patients without
cGvHD; DIPSS was predictive of survival
Scott [21] 1990-2009 170 51.5 (12-78) Multiple NR 34% at 5 yr 57% at 5 yr 57% at 5 yr Post-HCT success was dependent on pre-HCT DIPSS
scores
RIC indicates reduced-intensity conditioning; NRM, nonrelapse mortality; PFS, progression-free survival; OS, overall survival; NR, not reported; cGvHD, chronic graft-versus-host disease; DLI, donor lymphocyte infusion; Bu,
busulfan; Cy, cyclophosphamide; AHCT, allogeneic HCT; Flu, ﬂudarabine; URD, unrelated donor.
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regarding suitability for HCT [29]. In a report of results in 30
patients, 60 to 78 years of age, Samuelson et al. [19] showed
an overall survival of 45% and progression-free survival of
40% at 3 years. No signiﬁcant differences in survival were
noted between patients 60 to 65 years of age and those 66 to
78 years of age. Transplantation-associated mortality was
13% at day 100 after HCT.
Scott et al. presented yet another retrospective analysis of
HCT results in 170 patients, 12 to 78 years of age, with PMF,
post-PV MF, or post-ET MF. These authors used the DIPSS [6]
to prognosticate transplantation outcome in dependence of
the DIPSS score [21]. DIPSS considers patient age, the pres-
ence of symptoms (eg, night sweats), anemia (Hgb < 10 g/L),
leukocytosis (WBC 25109/L), and circulating myeloblasts
(1%) (Table 1). Overall survival and progression-free sur-
vival after HCT were closely correlated with pre-HCT DIPSS
classiﬁcation (Table 3). The probability of survival was
approximately 80% in patients in the lowest DIPSS risk group
(score 0) and 40% in the highest risk group (score > 4). The
incidence of disease relapse was similar for all DIPSS cate-
gories; however, nonrelapse mortality increased progres-
sively with higher DIPSS risk, presumably related to disease
manifestations, in particular ﬁbrosis, in nonhematopoietic
organs such as liver and lungs, providing another argument
in favor of earlier HCT. In this particular cohort, some patients
have been followed for 2 decades after HCT and remain in
remission.Disease Progression and Timing of HCT
Based on data reported to date, it is challenging to decide
upon the ideal time for HCT. Therefore, a decision analysis
was conducted restricted to patients with PMF, based on data
on 190 patients who underwent transplantation at European
centers or the Fred Hutchinson Cancer Research Center in
Seattle, and 248 patients, treated at European centers with
conventional non-HCT modalities [30]. Results in patients
followed for as long as 30 years showed a clear advantage
of HCT for patients in DIPSS categories intermediate-2
(scores 3 and 4) and high (scores > 4). The data also indi-
cate that patients in low DIPSS risk group have superior life
expectancy with conventional management. DIPSS group
intermediate-1 comprises patients in whom recommenda-
tions should be made on an individual basis. Of course,
as MPNs progress, extramedullary manifestations tend to
become more prominent and the patient may acquire new
comorbidities, underscoring the need for close monitoring
and sequential reassessment of patient and disease risk pa-
rameters to avoid missing the optimum time for HCT.
Patients who are “triple negative (nonmutated JAK2, MPL1,
and CALR)” [31,32] and patients with ASXL1 mutations in theTable 3
Median Survival by DIPSS, Without and With Transplantation*
DIPSS Risky Median Survival, yr
No Transplantation
(at reporting)
Transplantation
(median follow-up 5.9)
Low Not reached Not reached
Intermediate 1 14.2 Not reached
Intermediate 2 4 7
High 1.5 2.5
* No data on HCT outcome by MIPSS scores (see Table 1) have been
reported to date.
y References [6,26].presence of wild-type CALR [33] have a more aggressive
disease course [34]. These observations are reﬂected in the
modiﬁed DIPSS (Table 1) Those patients should probably be
considered for early HCT.
As stated above, patients whose disease has accelerated
(increase in blood or marrow myeloblast count to >10%,
decline in platelet count to <50  109/L, abnormalities of
chromosome 17) or progressed to frank AML have a median
life expectancy of less than 1 year [35]. Although HCT is the
only promising treatment strategy, outcome tends to be
inferior to that in patients with less advanced disease
because of a higher risk of relapse and nonrelapse mortality
[21]. Nevertheless, Ciurea et al. reported a long-term success
rate of 40% in a small cohort of patients who received
“debulking” treatment followed by HCT [36]. Similar results
were reported by Kennedy et al., who showed a 2-year
overall survival of 47% in patients responding to chemo-
therapy and undergoing HCT [3]. Alchalby et al. [37] reported
a 1-year treatment-related mortality of 28% and a 3-year
progression-free survival of 26% among 46 patients whose
MPN had evolved to AML. The major cause of failure was
disease relapse, which occurred in 47% of patients.
Based on a comprehensive evidence review, an inter-
national group of experts (European LeukemiaNet) recom-
mends allogeneic HCT for patients with MPN with
a projected median life expectancy of less than 5 years,
which, therefore, includes patients in DIPSS categories
intermediate-2 and high, as well as patients with acceler-
ated disease and transformation to AML [38].
Patient Age and Transplantation
In patients with myeloﬁbrosis up to 60 or 65 years of age,
allogeneic HCT is considered standard therapy, both for those
with PMF and those with post-PV and post-ET MF [38].
Published data on the use of allogeneic HCT for older patients
with MPN, speciﬁcally for patients who are typically covered
by Medicare, are limited. The analysis by Samuelson, pre-
sented above, shows a probability of long-term survival in
the range of 30% [19]. Alchalby et al. suggested a model to
predict survival after reduced-intensity conditioning trans-
plantation in patients with MF in which constitutional
symptoms, nonmutated JAK2, and age >57 years predicted
inferior outcome [16].
However, transplantation outcomes have been
improving. Data from the Center for International Blood and
Marrow Transplant Research on 254 patients ages 60 years
who received allogeneic HCT for MF from 2008 to 2013 show
a day 100 survival of 83% and a 1-year survival rate of 61%.
A report from the Fred Hutchinson Cancer Research Center
on 22 patients up to 65 years of age who underwent trans-
plantation for MPN showed a day 100 survival of 100% [27].
The oldest long-term survivor in the report by Scott et al. was
78 years old at the time of HCT [21].
SUMMARY AND CONCLUSIONS
Although ideally one would like to see results from a
prospective trial comparing HCT with nontransplantation
therapy for patients with MPN, considering the rarity of
these disorders and limited resources, it is unrealistic to
expect that such a trial will be conducted. Thus, the present
data, while not exhaustive, represent the best available evi-
dence in support of HCT for patients with MPNs, including
patients in the seventh or even eighth decade of life. Survival
probabilities, certainly for patients in DIPSS risk groups
intermediate-2 and high, are signiﬁcantly higher after HCT
H.J. Deeg et al. / Biol Blood Marrow Transplant 21 (2015) 1883e1887 1887than observed with conservative therapy. Comorbidities, in
addition to disease classiﬁcation (by DIPSS), signiﬁcantly
affect post-HCT outcome. As the probability of comorbidities
increases with age, the selection of older individuals for HCT
is profoundly affected by the presence of comorbidities. This
is true for patients with MPN as it is for patients with other
diagnoses. However, selection of the appropriate ﬁt patients
for HCT has led to rewarding results, and HCT for MPN should
not be withheld solely on the basis of age.
Currently, MF is not 1 of the indications listed in NCD
110.8.1 and, therefore, is not covered by Medicare insurance.
This represents a major access barrier to effective treatment
for patients with these diseases. It appears from available
data, however, that it is time to reassess this scenario and, in
view of progressively improving results with HCT, provide
insurance coverage for appropriately selected older patients
with MPN.
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